UNITY Biotechnology (UBX, Financial) has unveiled the complete 36-week findings from their Phase 2b ASPIRE trial, focusing on the intravitreal treatment UBX1325 for patients with diabetic macular edema who have not responded well to prior anti-VEGF therapies. Earlier data from the 24-week and interim 36-week periods showed that UBX1325 was generally comparable to aflibercept at most checkpoints, aside from the weeks 20 and 24 average, the main study goal.
The Phase 2b ASPIRE trial confirms that UBX1325 delivered visual gains in Best-Corrected Visual Acuity on par with a leading anti-VEGF product by week 36. Additionally, UBX1325 often outperformed aflibercept in patients with more aggressive forms of the disease. Importantly, the treatment maintained a strong safety and tolerability profile, without any reports of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis in multiple studies to date.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Unity Biotechnology Inc (UBX, Financial) is $5.00 with a high estimate of $6.00 and a low estimate of $4.00. The average target implies an upside of 346.43% from the current price of $1.12. More detailed estimate data can be found on the Unity Biotechnology Inc (UBX) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Unity Biotechnology Inc's (UBX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
